ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP, een biofarmaceutisch bedrijf dat innovatieve behandelingen van zeldzame kankervormen en weesziekten ontwikkelt door de inkapseling van medicijnen in rode bloedcellen (ERYCAPS platform) heeft vandaag aangekondigd dat het haar “Document de Référence” voor 2017 voor het jaar eindigend op 31 december 2017, met inbegrip van het beheersverslag en het jaarlijks financieel verslag bij de “Autorité des Marchés Financiers (AMF)” en haar jaarverslag op Form 20-F voor het jaar eindigend op 31 december 2017 bij de Securities and Exchange Commission (SEC), heeft gedeponeerd.

Deze documenten zijn beschikbaar op de Investors-rubriek van de corporate website van (www.erytech.com). Daarnaast is het “Document de Référence” ook beschikbaar op de website van de Autorité des marchés financiers (AMF) (http://www.amf-france.org) en het jaarverslag op Form 20-F op de website van de SEC (www.sec.gov). Gedrukte exemplaren van deze documenten zijn eveneens gratis verkrijgbaar door een aanvraag per post te richten aan ERYTECH Pharma, Bâtiment Adénine, 60 Avenue Rockefeller, 69008 in Lyon (Frankrijk).

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP),the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC).

These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also available free of charge, by sending a postal request to the registered offices of ERYTECH Pharma, Bâtiment Adénine, 60 Avenue Rockefeller, 69008 in Lyon (France).

About ERYTECH: www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180424006284/en/

Contacts

ERYTECH
Naomi Eichenbaum
Director Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
ERYTECH@newcap.eu